Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

A patient with treatment-resistant obsessive-compulsive disorder received psilocybin and was followed for a year. His OCD symptoms markedly improved, with the YBOCS score dropping from 24 to between 0 and 2. Broader gains included better emotional connection, social and work functioning, and quality of life. This individual was an early participant in an ongoing controlled study. The results are preliminary but suggest that carefully monitored and supported psychedelic treatment may hold therapeutic potential for obsessions and compulsions.

Study at a glance

Abstract

Classic psychedelics, such as psilocybin, act on the brain's serotonin system and produce striking psychological effects. Early work in the 1950s and 1960s and more recent controlled studies suggest benefit from psychedelic treatment in a number of conditions. A few case reports in recreational users and a single experimental study suggest benefit in patients with obsessive-compulsive disorder (OCD), but careful clinical data and long-term follow-up have been lacking. Here we describe a case of a patient with refractory OCD treated with psilocybin and followed prospectively for a year, with marked symptomatic improvement. We provide qualitative and quantitative detail of his experience during and after treatment. Improvement in OCD symptoms (YBOCS declined from 24 to 0-2) was accompanied by broader changes in his relationship to his emotions, social and work function, and quality of life. This individual was an early participant in an ongoing controlled study of psilocybin in the treatment of OCD (NCT03356483). These results are preliminary but promising, motivating ongoing investigations of the therapeutic potential of appropriately monitored and supported psychedelic treatment in the treatment of patients with obsessions and compulsions.